

Fatemeh Pourrajab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3221081/publications.pdf>

Version: 2024-02-01

36
papers

737
citations

566801

15
h-index

552369

26
g-index

40
all docs

40
docs citations

40
times ranked

1364
citing authors

#	ARTICLE	IF	CITATIONS
1	Transposable elements, contributors in the evolution of organisms (from an arms race to a source of) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	8
2	Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design. Journal of Cellular and Molecular Medicine, 2021, 25, 5842-5856.	1.6	8
3	The Impact of 6-Thioguanine on Epigenetics of Acute Myeloid Leukemia. Annals of Cancer Research and Therapy, 2021, 29, 121-125.	0.1	0
4	Ara-C elicits apoptosis and inhibits proliferation of human lymphoblastic leukemia Nalm6 cell lines by down regulation of HDAC3 and DNMT3B and up regulation of DNMT3A. Annals of Cancer Research and Therapy, 2021, 29, 47-54.	0.1	0
5	Metformin downregulates miR223 expression in insulin-resistant 3T3L1 cells and human diabetic adipose tissue. Endocrine, 2020, 70, 498-508.	1.1	10
6	<p>Ginger Extract Increases GLUT-4 Expression Preferentially Through AMPK Than PI3K Signalling Pathways in C2C12 Muscle Cells</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3231-3238.	1.1	7
7	<p>Molecular Basis for Pathogenicity of Human Coronaviruses</p>. Infection and Drug Resistance, 2020, Volume 13, 2385-2405.	1.1	8
8	Descending Expression of miR320 in Insulin-Resistant Adipocytes Treated with Ascending Concentrations of Metformin. Biochemical Genetics, 2020, 58, 661-676.	0.8	6
9	<p>Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia</p>. Journal of Experimental Pharmacology, 2020, Volume 12, 107-128.	1.5	9
10	<p>Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia</p>. Cancer Management and Research, 2020, Volume 12, 2231-2253.	0.9	30
11	Development of An Artificial Male Germ Cell Niche Using Electrospun Poly Vinyl Alcohol/Human Serum Albumin/Gelatin Fibers. Cell Journal, 2019, 21, 300-306.	0.2	5
12	Effects of a <scp><i>Peganum harmala</i></scp> (Zygophyllaceae) preparation for root canal disinfection. Phytotherapy Research, 2018, 32, 672-677.	2.8	8
13	Ectopic microRNAs used to preserve human mesenchymal stem cell potency and epigenetics. EXCLI Journal, 2018, 17, 576-589.	0.5	3
14	Sirt1 and Parp1 as epigenome safeguards and microRNAs as SASP-associated signals, in cellular senescence and aging. Ageing Research Reviews, 2017, 40, 120-141.	5.0	42
15	Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases. BioFactors, 2017, 43, 737-759.	2.6	14
16	Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 11-17.	1.4	9
17	Circulating miR-126 and miR-499 Reflect Progression of Cardiovascular Disease; Correlations with Uric Acid and Ejection Fraction. Heart International, 2016, 11, heartint.500022.	0.4	22
18	Extract of Dorema aucheri induces PPAR- β for activating reactive oxygen species metabolism. Journal of Herbal Medicine, 2016, 6, 171-179.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Elevated levels of miR-499 protect ischemic myocardium against uric acid in patients undergoing off-pump CABG. <i>Cor Et Vasa</i> , 2016, 58, e600-e608.	0.1	3
20	Micro RNA s; easy and potent targets in optimizing therapeutic methods in reparative angiogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2702-2714.	1.6	7
21	Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach. <i>Molecular and Cellular Therapies</i> , 2015, 3, 4.	0.2	53
22	The master switchers in the aging of cardiovascular system, reverse senescence by microRNA signatures; as highly conserved molecules. <i>Progress in Biophysics and Molecular Biology</i> , 2015, 119, 111-128.	1.4	20
23	Massive pericardial effusion and rhabdomyolysis secondary to untreated severe hypothyroidism: the first report. <i>Acta Clinica Belgica</i> , 2014, 69, 375-378.	0.5	6
24	Application of stem cell/growth factor system, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields. <i>International Journal of Cardiology</i> , 2014, 173, 12-19.	0.8	31
25	MicroRNA-based system in stem cell reprogramming; differentiation/dedifferentiation. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 55, 318-328.	1.2	16
26	Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine. <i>International Journal of Cardiology</i> , 2013, 163, 125-131.	0.8	24
27	Circulating levels of interleukin (IL)-12 and IL-13 in <i>Helicobacter pylori</i> -infected patients, and their associations with bacterial CagA and VacA virulence factors. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 342-349.	1.5	24
28	Novel immunomodulatory function of 1,3,4-thiadiazole derivatives with leishmanicidal activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1968-1978.	1.3	11
29	Cell death features induced in <i>Leishmania major</i> by 1,3,4-thiadiazole derivatives. <i>Experimental Parasitology</i> , 2012, 132, 116-122.	0.5	17
30	Synthesis and antileishmanial activity of 5-(5-nitroaryl)-2-substituted-thio-1,3,4-thiadiazoles. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2011, 26, 123-128.	2.5	21
31	Novel antileishmanial chalconoids: Synthesis and biological activity of 1- or 3-(6-chloro-2H-chromen-3-yl)propen-1-ones. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1424-1429.	2.6	47
32	Chromene-Based Synthetic Chalcones as Potent Antileishmanial Agents: Synthesis and Biological Activity. <i>Chemical Biology and Drug Design</i> , 2010, 75, 590-596.	1.5	71
33	Selective leishmanicidal effect of 1,3,4-thiadiazole derivatives and possible mechanism of action against <i>Leishmania</i> species. <i>Experimental Parasitology</i> , 2009, 121, 323-330.	0.5	41
34	Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: Synthesis and in vitro biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 1758-1762.	2.6	84
35	Leishmanicidal Evaluation of Novel Synthetic Chromenes. <i>Archiv Der Pharmazie</i> , 2008, 341, 787-793.	2.1	14
36	Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuranyl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-arylpiperazines. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 4509-4515.	1.4	52